DK3395812T3 - Krystallinske former og fremgangsmåder til fremstilling af kondenserede azacykler (cannabinoid-receptor-modulatorer) - Google Patents

Krystallinske former og fremgangsmåder til fremstilling af kondenserede azacykler (cannabinoid-receptor-modulatorer) Download PDF

Info

Publication number
DK3395812T3
DK3395812T3 DK18164225.7T DK18164225T DK3395812T3 DK 3395812 T3 DK3395812 T3 DK 3395812T3 DK 18164225 T DK18164225 T DK 18164225T DK 3395812 T3 DK3395812 T3 DK 3395812T3
Authority
DK
Denmark
Prior art keywords
azacycles
fused
preparation
methods
crystalline forms
Prior art date
Application number
DK18164225.7T
Other languages
Danish (da)
English (en)
Inventor
Anthony C Blackburn
Sangdon Han
Robert M Jones
Antonio Garrido Montalban
Biman B Pal
Jaimie Karyn Rueter
Original Assignee
Arena Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharm Inc filed Critical Arena Pharm Inc
Application granted granted Critical
Publication of DK3395812T3 publication Critical patent/DK3395812T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK18164225.7T 2011-02-25 2012-02-24 Krystallinske former og fremgangsmåder til fremstilling af kondenserede azacykler (cannabinoid-receptor-modulatorer) DK3395812T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161446732P 2011-02-25 2011-02-25
US201161448542P 2011-03-02 2011-03-02
EP12709201.3A EP2678330A1 (en) 2011-02-25 2012-02-24 Crystalline forms and processes for the preparation of condensed azacycles ( cannabinoid receptor modulators)

Publications (1)

Publication Number Publication Date
DK3395812T3 true DK3395812T3 (da) 2022-11-28

Family

ID=45841624

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18164225.7T DK3395812T3 (da) 2011-02-25 2012-02-24 Krystallinske former og fremgangsmåder til fremstilling af kondenserede azacykler (cannabinoid-receptor-modulatorer)

Country Status (20)

Country Link
US (4) US9458136B2 (enExample)
EP (3) EP3395812B8 (enExample)
JP (1) JP5945554B2 (enExample)
KR (1) KR102036932B1 (enExample)
CN (1) CN103608343B (enExample)
AU (1) AU2012222146B2 (enExample)
BR (1) BR112013021549B1 (enExample)
CA (1) CA2827057C (enExample)
CL (1) CL2013002436A1 (enExample)
CO (1) CO6852066A2 (enExample)
DK (1) DK3395812T3 (enExample)
EA (1) EA035989B1 (enExample)
ES (1) ES2932441T3 (enExample)
IL (1) IL227782A (enExample)
MX (1) MX346533B (enExample)
MY (1) MY165767A (enExample)
PH (1) PH12013501726A1 (enExample)
SG (1) SG192817A1 (enExample)
WO (1) WO2012116276A1 (enExample)
ZA (1) ZA201306402B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201404925TA (en) * 2009-08-28 2014-10-30 Arena Pharm Inc Cannabinoid receptor modulators
US9597340B2 (en) 2011-02-25 2017-03-21 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
CN103492369B (zh) * 2011-02-25 2019-03-29 艾尼纳制药公司 大麻素受体调节剂
EA035989B1 (ru) * 2011-02-25 2020-09-09 Арена Фармасьютикалз, Инк. Кристаллические формы и способы получения модуляторов каннабиноидного рецептора
WO2016085941A1 (en) * 2014-11-25 2016-06-02 Arena Pharmaceuticals, Inc. Processes for the preparation of cannabinoid receptor modulators
MX2018012361A (es) * 2016-04-10 2019-05-30 Arena Pharm Inc Metodos de tratamiento con agonistas selectivos del receptor cb2.
EP3621619B1 (en) 2017-05-08 2023-06-28 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of visceral pain
WO2018208847A1 (en) 2017-05-08 2018-11-15 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of pain from inflammatory bowel disease
CN114391011A (zh) * 2019-09-12 2022-04-22 四川海思科制药有限公司 一种六氢化苯并吡唑衍生物及其制备
TW202330496A (zh) 2021-10-05 2023-08-01 美商艾尼納製藥公司 用於製備大麻素受體調節劑之結晶形式及方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3964478B2 (ja) 1995-06-30 2007-08-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬
AU781266B2 (en) 1999-04-28 2005-05-12 Sanofi-Aventis Deutschland Gmbh Di-aryl acid derivatives as PPAR receptor ligands
WO2003049727A1 (en) 2001-12-07 2003-06-19 Virginia Commonwealth University Treatment of neoplasia
SE0300010D0 (sv) 2003-01-07 2003-01-07 Astrazeneca Ab Novel Compounds
WO2005123677A1 (en) 2004-06-16 2005-12-29 Actelion Pharmaceuticals Ltd 4-carbonyl substituted 1,1,2-trimethyl-1a,4,5,5a-tetrahydro-1h-4-aza-cyclopropa'a!pentalene derivatives as agonists for the g-protein-coupled receptor s1p1/edg1 and immunosuppressive agents
BRPI0513104A (pt) 2004-07-12 2008-04-29 Cadila Healthcare Ltd composto, composição farmacêutica, método para o tratamento de doenças associadas com os receptores de canabinóide, medicamento para o tratamento/redução de doenças associadas com os receptores de canabinóides, uso do composto, processo para a preparação do composto e intermediário
FR2875230A1 (fr) * 2004-09-13 2006-03-17 Sanofi Aventis Sa Derives de pyrazole condense, leur preparation et leur application en therapeutique
DE102004054666A1 (de) 2004-11-12 2006-05-18 Bayer Cropscience Gmbh Substituierte Pyrazol-3-carboxamide, Verfahren zur Herstellung und Verwendung als Herbizide und Pflanzenwachstumsregulatoren
PE20060949A1 (es) 2004-12-23 2006-10-11 Arena Pharm Inc Derivados fusionados de pirazol como agonistas del receptor de niacina
UA93390C2 (ru) * 2005-06-02 2011-02-10 Гленмарк Фармасьютикалс C.A. Лиганды каннабиноидных рецепторов, фармацевтическая композиция (варианты), которая их содержит, и способ их получения
CA2613678A1 (en) * 2005-06-02 2006-12-07 Glenmark Pharmaceuticals S.A. Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
ATE459352T1 (de) 2006-07-04 2010-03-15 Janssen Pharmaceutica Nv Benzimidazol-cannabinoid-agonisten mit einer substituierten heterocyclischen gruppe
KR20090069318A (ko) 2006-09-25 2009-06-30 베링거 인겔하임 인터내셔날 게엠베하 Cb2 수용체를 조절하는 화합물
US8481574B2 (en) 2006-10-12 2013-07-09 Abbott Laboratories Compounds as cannabinoid receptor ligands
WO2008048914A1 (en) 2006-10-17 2008-04-24 Boehringer Ingelheim International Gmbh Polycyclic compounds which modulate the cb2 receptor
RU2009117203A (ru) 2006-11-03 2010-12-10 Гленмарк Фармасеутикалс С.А. (Ch) Новые лиганды каннабиноидных рецепторов, фармацевтические композиции, содержащие данные лиганды, и способы их получения
US8173638B2 (en) 2006-11-21 2012-05-08 Boehringer Ingelheim International Gmbh Compounds which modulate the CB2 receptor
WO2008085302A1 (en) 2006-12-20 2008-07-17 Merck & Co., Inc. Imidazopyridine analogs as cb2 receptor modulators, useful in the treatment of pain, respiratory and non-respiratory diseases
US20080161340A1 (en) 2006-12-20 2008-07-03 Cara Therapeutics, Inc. Tetrahydroquinilinones, tetrahydronaphthyridones and derivatives thereof
WO2008109007A1 (en) 2007-03-02 2008-09-12 Cara Therapeutics, Inc. Bridged phenanthridines
WO2008114619A1 (ja) 2007-03-16 2008-09-25 Kyocera Corporation 誘電体磁器およびコンデンサ
ES2548764T3 (es) 2007-03-30 2015-10-20 Janssen Pharmaceutica N.V. Agonistas de cannabinoides de bencimidazol
WO2008157500A1 (en) 2007-06-17 2008-12-24 Kalypsys, Inc. Aminoquinazoline cannabinoid receptor modulators for treatment of disease
JP5485148B2 (ja) 2007-06-21 2014-05-07 カラ セラピューティクス インコーポレイテッド 置換イミダゾ複素環
US8338623B2 (en) 2007-07-09 2012-12-25 Abbvie Inc. Compounds as cannabinoid receptor ligands
US7943658B2 (en) 2007-07-23 2011-05-17 Bristol-Myers Squibb Company Indole indane amide compounds useful as CB2 agonists and method
US20120004222A1 (en) 2007-08-21 2012-01-05 Zhicai Wu Cb2 receptor ligands for the treatment of pain
UA104010C2 (en) 2008-12-18 2013-12-25 Эли Лилли Энд Компани Purine compounds
US7741350B1 (en) * 2009-01-28 2010-06-22 Cara Therapeutics, Inc. Bicyclic pyrazolo-heterocycles
US8653127B2 (en) 2009-01-28 2014-02-18 Cara Therapeutics, Inc. Bicyclic pyrazolo-heterocycles
SG10201404925TA (en) * 2009-08-28 2014-10-30 Arena Pharm Inc Cannabinoid receptor modulators
WO2012116278A1 (en) 2011-02-25 2012-08-30 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
CN103492369B (zh) * 2011-02-25 2019-03-29 艾尼纳制药公司 大麻素受体调节剂
US9597340B2 (en) 2011-02-25 2017-03-21 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
EA035989B1 (ru) * 2011-02-25 2020-09-09 Арена Фармасьютикалз, Инк. Кристаллические формы и способы получения модуляторов каннабиноидного рецептора

Also Published As

Publication number Publication date
MY165767A (en) 2018-04-23
AU2012222146A1 (en) 2013-09-19
US10981895B2 (en) 2021-04-20
US20210380560A1 (en) 2021-12-09
EP4166552B1 (en) 2025-03-19
BR112013021549B1 (pt) 2022-01-11
US9458136B2 (en) 2016-10-04
US20170144993A1 (en) 2017-05-25
JP5945554B2 (ja) 2016-07-05
IL227782A0 (en) 2013-09-30
SG192817A1 (en) 2013-09-30
US11560369B2 (en) 2023-01-24
AU2012222146B2 (en) 2017-05-11
EP3395812B8 (en) 2022-11-02
US20140135345A1 (en) 2014-05-15
CN103608343A (zh) 2014-02-26
NZ614787A (en) 2014-08-29
EA201391233A1 (ru) 2014-02-28
JP2014506602A (ja) 2014-03-17
US10183930B2 (en) 2019-01-22
EP3395812A1 (en) 2018-10-31
ES2932441T3 (es) 2023-01-19
CA2827057C (en) 2022-06-07
CL2013002436A1 (es) 2014-01-24
US20190308952A1 (en) 2019-10-10
BR112013021549A2 (pt) 2016-11-01
CO6852066A2 (es) 2014-01-30
IL227782A (en) 2017-02-28
PH12013501726A1 (en) 2014-01-13
WO2012116276A1 (en) 2012-08-30
ZA201306402B (en) 2022-03-30
EA035989B1 (ru) 2020-09-09
EP4166552A1 (en) 2023-04-19
KR20140025353A (ko) 2014-03-04
MX2013009760A (es) 2014-06-11
EP3395812B1 (en) 2022-09-28
MX346533B (es) 2017-03-14
KR102036932B1 (ko) 2019-10-25
CN103608343B (zh) 2019-02-01
EP2678330A1 (en) 2014-01-01
CA2827057A1 (en) 2012-08-30

Similar Documents

Publication Publication Date Title
DK3395812T3 (da) Krystallinske former og fremgangsmåder til fremstilling af kondenserede azacykler (cannabinoid-receptor-modulatorer)
DK2659675T3 (da) Fremgangsmåde for billedsegmentering under anvendelse af søjler
DK2766392T3 (da) Fremgangsmåde til oprensning af antistoffer
DK3321276T3 (da) Fusionsproteiner til behandling af metaboliske lidelser
DK3824991T3 (da) Fremgangsmåde til forberedelse af lithiumsulfat
DK2558199T3 (da) Fremgangsmåde til fremstilling af bårne ædelmetalkatalysatorer via hydrothermal deponering
DK2718404T3 (da) Fremgangsmåde til fremstilling af flydende carbonhydrider
DK3141548T3 (da) Fremgangsmåder og mellemprodukter til fremstilling af azaindoler
DK2768857T3 (da) Fremgangsmåder til oprensning af antistoffer
DK2654471T3 (da) Aerosoldannende system med midler til frakobling af forbrugsstof
DK2739293T3 (da) Fremgangsmåder og sammensætninger til frembringelse af vaccinavirus
DK2489670T3 (da) Fremgangsmåde til fremstilling af aminosyre-chelatforbindelser, aminosyre-chelatforbindelser og anvendelse af aminosyre-chelatforbindelser
DK2386683T3 (da) Fremgangsmåde til fremstilling af gel-baserede kompositmaterialer
DK2768796T3 (da) Fremgangsmåde til fremstilling af quinolin-derivater
DK2598457T3 (da) Vandig opslæmning af amorf silica og fremgangsmåde til fremstilling heraf
DK2496562T3 (da) Fremgangsmåde til fremstilling af calcobutrol
DK2531526T3 (da) Fremgangsmåde til opnåelse af antistoffer
DK3050883T3 (da) Fremgangsmåde til fremstilling af diazabicyclooctanderivater og mellemprodukter
DK3385252T3 (da) Cannabinoidreceptormodulatorer
DK3402201T3 (da) Fremgangsmåde til dekodning af et billede
DK3279214T3 (da) Fremgangsmåde til fremstilling af variable immunglobulin-enkeltdomæner
DK2627656T3 (da) Fremgangsmåde til fremstilling af dihydropteridinon og intermediater deraf
DK2822965T3 (da) FREMGANGSMÅDE TIL BERIGELSE AF IgA
DK2392548T3 (da) Fremgangsmåde til fremstilling af en amorf siliciumdioxid-sammensætning og beslægtet amorf siliciumdioxid-aluminiumoxid-samensætning
DK2661845T3 (da) Apparat og fremgangsmåde til modtagelse og videresendelse af data